share_log

F-1/A: Registration statement for securities of certain Canadian issuers (Amendment)

F-1/A: Registration statement for securities of certain Canadian issuers (Amendment)

F-1/A：證券登記表(修正)
美股sec公告 ·  05/20 16:24
Moomoo AI 已提取核心訊息
NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed an amendment to its Form F-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on May 20, 2024. The amendment pertains to the registration of up to 3,050,964 ordinary shares and 2,980,000 ordinary warrants for sale to the public. The ordinary warrants have an exercise price of $1.50 per share and are exercisable immediately upon issuance until April 15, 2029. Additionally, 70,964 ordinary shares were issued to the placement agent as partial consideration for their services in connection with the April 2024 offering. The company's ordinary shares and warrants are listed on The Nasdaq Capital Market under the symbols 'NRSN' and 'NRSNW,' respectively. The proceeds from the exercise of the warrants, if any, are intended for general corporate purposes and working capital. The registration statement also includes details on the company's ability to indemnify its officers and directors, and the legal and financial advisors involved in the filing.
NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed an amendment to its Form F-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on May 20, 2024. The amendment pertains to the registration of up to 3,050,964 ordinary shares and 2,980,000 ordinary warrants for sale to the public. The ordinary warrants have an exercise price of $1.50 per share and are exercisable immediately upon issuance until April 15, 2029. Additionally, 70,964 ordinary shares were issued to the placement agent as partial consideration for their services in connection with the April 2024 offering. The company's ordinary shares and warrants are listed on The Nasdaq Capital Market under the symbols 'NRSN' and 'NRSNW,' respectively. The proceeds from the exercise of the warrants, if any, are intended for general corporate purposes and working capital. The registration statement also includes details on the company's ability to indemnify its officers and directors, and the legal and financial advisors involved in the filing.
處於臨床階段的生物技術公司NeuroSense Therapeutics Ltd.（NeuroSense）已於2024年5月20日向美國證券交易委員會（SEC）提交了其F-1表格註冊聲明的修正案。該修正案涉及最多3,050,964股普通股和298萬份普通認股權證的註冊，以向公衆出售。普通認股權證的行使價爲每股1.50美元，可在發行後立即行使，直至2029年4月15日。此外，向配售代理人發行了70,964股普通股，作爲其與2024年4月發行相關的服務的部分對價。該公司的普通股和認股權證分別在納斯達克資本市場上市，代碼分別爲 “NRSN” 和 “NRSNW”。行使認股權證的收益（如果有）將用於一般公司用途和營運資金。註冊聲明還包括有關公司向其高管和董事以及參與申報的法律和財務顧問進行賠償的能力的詳細信息。
處於臨床階段的生物技術公司NeuroSense Therapeutics Ltd.（NeuroSense）已於2024年5月20日向美國證券交易委員會（SEC）提交了其F-1表格註冊聲明的修正案。該修正案涉及最多3,050,964股普通股和298萬份普通認股權證的註冊，以向公衆出售。普通認股權證的行使價爲每股1.50美元，可在發行後立即行使，直至2029年4月15日。此外，向配售代理人發行了70,964股普通股，作爲其與2024年4月發行相關的服務的部分對價。該公司的普通股和認股權證分別在納斯達克資本市場上市，代碼分別爲 “NRSN” 和 “NRSNW”。行使認股權證的收益（如果有）將用於一般公司用途和營運資金。註冊聲明還包括有關公司向其高管和董事以及參與申報的法律和財務顧問進行賠償的能力的詳細信息。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息